Is HZNP undervalued or overvalued?
As of 2025-03-19, the Intrinsic Value of Horizon Therapeutics PLC (HZNP) is 103.46 USD. This HZNP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 116.30 USD, the upside of Horizon Therapeutics PLC is -11.00%. This means that HZNP is overvalued by 11.00%.
The range of the Intrinsic Value is 66.49 - 251.13 USD
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 66.49 - 251.13 | 103.46 | -11.0% |
| DCF (Growth 10y) | 90.60 - 325.77 | 137.92 | 18.6% |
| DCF (EBITDA 5y) | 31.12 - 67.07 | 43.63 | -62.5% |
| DCF (EBITDA 10y) | 49.65 - 96.50 | 65.86 | -43.4% |
| Fair Value | 47.82 - 47.82 | 47.82 | -58.88% |
| P/E | 43.92 - 70.73 | 54.70 | -53.0% |
| EV/EBITDA | 22.16 - 75.38 | 39.96 | -65.6% |
| EPV | 42.53 - 54.24 | 48.39 | -58.4% |
| DDM - Stable | 25.54 - 123.40 | 74.47 | -36.0% |
| DDM - Multi | 49.48 - 185.30 | 78.04 | -32.9% |
| Market Cap (mil) | 26,631.54 |
| Beta | -0.28 |
| Outstanding shares (mil) | 228.99 |
| Enterprise Value (mil) | 26,724.37 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.32% |
| Cost of Debt | 5.11% |
| WACC | 7.08% |